Phase 3 N=855 Trial of Adjuvant Chemotherapy for Gastric Cancer
Stomach Cancer
Primary: Relapse-free Survival Rate — 67.0; 64.9 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=413 Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
Brain and Central Nervous System Tumors
Primary: Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors — 79.2; 83.3; 69.6; 86.7 probability of PFS at 2 years — p=0.8001
Phase 3 N=312 A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
Arthritis, Psoriatic
Primary: Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24. — 20.2; 43.7; 43.8; 43.8 Percentage of participants — p=<0.001
Phase 3 N=1,869 Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population
Encephalitis
Primary: Rate of Subjects With Serious Adverse Events and Medically Attended Adverse Events Until Day 56 After First Vaccination — 16.1; 14.2; 38.2; 42.2 percentage of…
Phase 3 N=1,262 Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis
Osteoporosis
Primary: Incidence of New or Worsening Vertebral Fractures in Osteoporotic Subjects Treated With Denosumab Compared to Placebo — 3.6; 10.3; 7.2 Vertebral fractures — p=0.0001
Phase 3 N=215 Prucalopride in Pediatric Subjects With Functional Constipation
Functional Constipation
Primary: Percent of Responders in the Last Four Weeks of the Double-Blind Treatment Period — 17.0; 17.8 percentage of subjects — p=0.9002
Phase 3 N=154 Long Term Administration Study of OPC-12759 Ophthalmic Suspension
Dry Eye Syndromes
Primary: Change From Baseline (CFB) in Fluorescein Corneal Staining (FCS) Score — -2.2; -2.7; -4.1; -4.6 FCS score — p=<0.001
Phase 3 N=445 A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Pulmonary Hypertension
Primary: 6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 12 — 29.6; 31.1; -5.6 Meters — p=<0.0001
Phase 3 N=389 Study of Pyridoxine for Hand-Foot Syndrome
Hand-foot Syndrome
Primary: Cumulative Dose of Capecitabine Until the Development of Grade 2 or Higher Hand-foot Syndrome — 70000; 70000 miligram per square meter
Phase 3 N=684 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
Facial Rhytides · Crow's Feet Lines · Glabellar Lines
Primary: Percentage of Participants Achieving a Grade of None or Mild at Maximum Smile Based on the Investigator Facial Wrinkle Scale Assessment of the Severity of Crow's Feet…
Phase 3 N=409 Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis
Arthritis, Psoriatic
Primary: American College of Rheumatology 20 (ACR20) Response at Week 12 — 24.3; 58.0; 51.9 percentage of participants — p=<0.001
Phase 3 N=176 An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure
Reversal of Coagulopathy
Primary: Percentage of Participants Achieving Hemostatic Efficacy During Surgery — 89.7; 75.3 percentage of participants
Phase 3 N=40 Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation Patients
Herpes Simplex
Primary: Number of Participants With a Herpes Simplex Virus (HSV) Infection — 0; 0 Participants
Phase 3 N=202 PERgoveriS In Stratified Treatment for Assisted Reproductive Technique
Assisted Reproductive Techniques · Reproductive Technology, Assisted
Primary: Total Number of Oocytes Retrieved — 10.9; 9.7 oocytes
Phase 3 N=2,832 ACTIVE: Advanced Cognitive Training for Independent and Vital Elderly
Aging · Healthy
Primary: Changes in Cognitive Abilities of Memory From Baseline to Year 10 — -10.6; -11.2; -12.7; -9.4 units on a scale — p=0.43